Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;11(5):536-45.
doi: 10.2174/138945010791011947.

A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials

David J Hunter  1 , Elena Losina, Ali Guermazi, Deb Burstein, Marissa N Lassere, Virginia Kraus
Affiliations
Review

A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials

David J Hunter et al. Curr Drug Targets. 2010 May.

Abstract

This narrative review outlines the work done in other fields with regards biomarker validation and qualification and the lessons that we may learn from this experience. Defining a universally agreed upon path for biomarker validation and qualification is urgently needed to circumvent many of the hurdles faced in OA therapeutic development irrespective of whether we are discussing biochemical markers, imaging markers or other measures. This review proposes a path that may be suitable for osteoarthritis and poses some logical next steps that will take us in this direction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chart depicting the organization of EDRN. Modified from: http://edrn.jpl.nasa.gov/about-edrn/image-1.gif/image_view
See this image and copyright information in PMC

References

    1. Kluft C. Principles of use of surrogate markers and endpoints. Maturitas. 2004;47(4):293–8. - PubMed
    1. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Disease Markers. 2002;18(2):41–6. - PMC - PubMed
    1. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development [Review] [103 refs] Br J Pharmacol. 2008;153(4):646–56. - PMC - PubMed
    1. Richter WS. Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imag. 2006;33(Suppl 1):6–10. - PubMed
    1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Economics. 2003;22(2):151–85. - PubMed